GlassScriptPhysician profile
Scott Allen Buck
NPI 1801856943
$5,433.62
in general payments reported to CMS, 2019-2025
20 companies · $172 in 2025
The $172 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $585 · 2020: $208 · 2021: $507 · 2022: $3,104 · 2023: $317 · 2024: $540 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,029.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,028.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $2,816.48 | 2022 | |
| Alcon Vision LLC | $1,018.49 | 2019-2024 | Clareon, Duovisc, Rocklatan |
| Coopervision INC. | $307.15 | 2019-2025 | Myday Contact Lens |
| Apellis Pharmaceuticals, INC. | $221.49 | 2023-2025 | Syfovre |
| Johnson & Johnson Vision Care, INC. | $209.27 | 2019-2025 | |
| Allergan, INC. | $129.87 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $110.57 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $102.56 | 2019-2022 | |
| Biogen, INC. | $94.86 | 2024 | Byooviz |
| Bausch & Lomb Americas INC. | $76.00 | 2022-2025 | Infuse, Xiidra, Miebo |
| Ocular Therapeutix, INC. | $56.07 | 2019-2022 | |
| Abbvie INC. | $55.69 | 2023-2025 | Ozurdex |
| Kala Pharmaceuticals, INC. | $54.09 | 2021 | |
| Shire North American Group INC | $34.34 | 2019 | |
| Sight Sciences, INC. | $33.81 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $32.07 | 2024 | Xdemvy |
| Genentech USA, INC. | $22.96 | 2025 | Vabysmo |
| Johnson & Johnson Surgical Vision, INC. | $21.94 | 2024 | |
| Glaukos Corporation | $21.46 | 2019 | |
| Horizon Therapeutics Plc | $14.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Buck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.